SUMMARY

DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT

GOAL

- ✓ Identify patients in the early stages of a progressive disease who would benefit from palliative care services
- ✓ Identify and refer patients who would benefit from Hospice care
 ✓ Identify and document patients' end of life preferences using Advance Directive 7421 and POLST 7385
- ✓ Refer for Compassionate Release or Medical Parole as medically appropriate
- \checkmark Provide relief from pain and other distressing symptoms

Frequent hospitalizations/interventions

ALERTS

- Uncontrolled pain
- Uncontrolled dyspnea
- Intolerable side effects with current treatment plan
- Patient with progressive illness without Advance Directive/Code Status
- Patients with progressive end stage disease including dementia, cirrhosis

DIAGNOSTIC CRITERIA/EVALUATION

	PALLIATIVE CARE	HOSPICE				
Who	 Patient has <i>either</i> a limited life expectancy (regardless of symptom burden or goals for care) or a significant symptom burden or goals for care exclusively to achieve and maintain comfort (regardless of prognosis or symptom burden) Provider: Can/should be provided by all Physicians, mid- 	 Patient has both a limited life expectancy (specifically < 6 mos) (See Table pg 13 for disease specific criteria) goals for care are exclusively to achieve and maintain comfort, regardless of the symptom burden Provider: Multidisciplinary team physician or mid-level with 				
	levels and nurses	special training or experience				
Where	All institutions/ most settings	Men CMF, Women CCWF				
	EVALUATION					

Step 1: Ask "Would I be surprised if this patient died within 2 years" Available tools include Performance Scales (Karnofsky/Palliative Performance Scale) and Disease Specific Prognostic Tools. (See **pages 3-5**)

Step 2: Initiate palliative care discussion. Discuss prognostic uncertainty and assess patient's goals. Utilize Advance Directive CDCR 7421 to elicit patient's choice of surrogate decision- maker and end of life wishes. (See page 6)

Step 3: Assess patient's palliative care needs including the domains of palliative care: Physical, Psychological, Social, Spiritual, Ethical, Cultural. Palliative care can be provided even as curative treatment is attempted. (See **page 6**)

Step 4: Develop or revise palliative care plan as indicated by the patients condition. Document plan in progress notes. (See **pages 7-12** for Medications/ Symptom Management). Consider whether patient meets criteria for Compassionate Release or Medical Parole.

Step 5: Consider does the patient meet hospice criteria? (Pg 13-14) As disease progresses complete POLST CDCR7385.

TREATMENT OPTIONS

Nonpharmacologic

General: Step back- can medical treatment plan can be simplified? (e.g. stop statin in patient with severe dementia?, stop labs?)

Ambulatory: Educate patient. Mental Health referral if anxious or depressed. Involve whole Primary Care Team as support.

Debilitated/Bed-bound: Position patient -watch for skin breakdown, artificial nutrition/hydration is rarely indicated.

Pharmacologic

Pain: Opioids are medication of choice in moderate -severe pain. Usually start with Immediate Release (IR) formulation for titration in acute pain and switch to long-acting when pain under control. Have breakthrough doses available. (See **pages 7 & 9**)

Constipation: Prevention is paramount, treatment choices for established constipation. (See page 12)

Dyspnea: Opioids are treatment of choice, anxiolytics can reduce anxiety component.


Nausea/Vomiting: Medication depends on causative mechanism, Metoclopramide a good first line choice.

MONITORING

- Continually reassess if care plan is accomplishing patients goals
- Periodically assess and document patient's end of life wishes in Progress Notes

Information contained in the guidelines is not a substitute for a health care professional's clinical judgment. Evaluation and treatment should be tailored to the individual patient and the clinical circumstances. Furthermore, using this information will not guarantee a specific outcome for each patient.





Health Care Guideline: Palliative Care, Third Edition, November 2009

SUMMARY

DECISION SUPPORT

DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT **SUMMARY**

STEP 1

Provider asks:"Would I be surprised if this patient died within two years?" Can use general Performance Status Tools (Karnofsky or PPS) Tools available from page 1 step 1

Karnofsky Performance Status Scale Definitions Rating (%) Criteria					
	100	Normal no complaints; no evidence of disease.			
Able to carry on normal activity and to work; no special care needed.	90	Able to carry on normal activity; minor signs or symptoms of disease.			
	80	Normal activity with effort; some signs or symptoms of disease.			
Unable to work; able to live at home	70	Cares for self; unable to carry on normal activity or to do active work.			
and care for most personal needs;	60	Requires occasional assistance, but is able to care for most of his personal needs			
varying amount of assistance needed.	50	Requires considerable assistance and frequent medical care.			
	40	Disabled; requires special care and assistance.			
Unable to care for self; requires equiva-	30	Severely disabled; hospital admission is indicated but death not imminent.			
lent of institutional or hospital care;	20	Very sick; hospital admission necessary; active supportive treatment necessary.			
disease may be progressing rapidly.	10	Moribund; fatal processes progressing rapidly.			
	0	Dead			

Palliative Performance Scale

The Palliative Performance Scale (PPS) is a modification of the Karnofsky and was designed for measurement of physical status in Palliative Care. Only 10% of patient with PPS score of < 50% would be expected to survive for > 6 months.

%	Ambulation	Activity and Evidence of Disease	Self-Care	Intake	Level of Consciousness
100	Full	Normal Activity No Evidence of Disease	Full	Normal	Full
90	Full	Normal Activity Some Evidence of Disease	Full	Normal	Full
80	Full	Normal Activity with Effort Some Evidence of Disease	Full	Normal or Reduced	Full
70	Reduced	Unable to do Normal Job / Work Some Evidence of Disease	Full	Normal or Reduced	Full
60	Reduced	Unable to do Hobby / House Work Significant Disease	Occasional Assistance Necessary	Normal or Reduced	Full or Confusion
50	Mainly Sit/Lie	Unable to do Any Work Extensive Disease	Considerable Assistance Required	Normal or Reduced	Full or Confusion
40	Mainly in Bed	As Above	Mainly Assistance	Normal or Reduced	Full or Drowsy or Confusion
30	Totally Bed Bound	As Above	Total Care	Reduced	Full or Drowsy or Confusion
20	As Above	As Above	Total Care	Minimal Sips	Full or Drowsy or Confusion
10	As Above	As Above	Total Care	Mouth Care Only	Drowsy or Coma
0	Death				

SUMMARY

PATIENT EDUCATION/SELF MANAGEMENT

STEP 1 (cont.)

Provider asks:

"Would I be surprised if this patient died within two years?" Can use Disease Specific Prognostic Tools.

DECISION SUPPORT

Disease Specific Prognostic Tools:

CANCER:

The Eastern Cooperative Oncology Group (ECOG) is one of the largest clinical cancer research organizations in the United States, and conducts clinical trials in all types of adult cancers. They developed the ECOG Performance Status: these criteria are used by providers and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis

	ECOG Performance Status					
Grade	ECOG					
0	Fully active, able to carry on all pre-disease performance without restriction.					
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.					
2	Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.					
3	Capable of only limited self care, confined to bed or chair more than 50% of waking hours.					
4	Completely disabled. Cannot carry on any self care. Totally confined to bed or chair.					
5	Dead					
Scoring	: ECOG > 3 roughly correlates with median survival of 3 months					
Oken, M.N	I., et. Al. Am J Clin Oncol 5:649-655, 1982 The Eastern Cooperative Oncology Group					

LIVER DISEASE:

Childs-Turcotte-Pugh is a tool used to help assess prognosis in patients with liver disease. Variations in the timing and subjectivity inherent in the scoring of the CTP (e.g. in grading ascites or encephalopathy) are its major limitations.

	s-Turcotte-Pugh Points *	Child's-Turcotte-Pugh Scoring					
	1	2	3	Class	Points	Survival	
Encephalopathy	None	Grade 1-2 (or participant-induced)	Grade 3-4 (or chronic)	Class A		95% 1 year survival 90% 2 year survival	
Ascites	None	Mild/Moderate (diuretic-responsive)	Severe (diuretic-refractory)	Class B	7-9	80% 1 year survival	
Bilirubin (mg/dL)	<2	2-3	>3			70% 2 year survival	
Albumin (g/dL)	>3.5	2.8-3.5	<2.8	Class C	10-15		
PT (sec prolonged or INR)	<4 <1.7	4-6 1.7-2.3	>6 >2.3	Class C	10-15	45% 1 year survival 38% 2 year survival	

HEART FAILURE:

Based on data from SUPPORT, Framingham, IMPROVEMENT, and other studies, 1-year mortality estimates are below. The National Hospice and Palliative Care Organization's guidelines for Heart Disease admission criteria include: NYHA class IV heart failure (Symptoms at rest)

New York Heart Association Functional Classification					
Class	Symptom Severity	1 year mortality estimates (Support Study)			
Class II Patients with slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	Mild	5-10%			
Class III Patients with marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	Moderate	10-15%			
Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased	Severe	30-40%			

July 2011	CCHCS Care Guide: Palliative Care						
SUMMARY	DECISION SUPPORT	PATIENT EDUCATION/SELI	- Management				
ISTEP 1 (cont.) Provider asks: "Would I be surprised if	this patient died within two years?"	Can use Disease Specific Prognostic	Tools.				
DEMENTIA: The National Hospice and appropriate for hospice enror its one or more specific demo • aspiration • multiple stage 3-4 ulcers	 billment, based on an expected six monthentia-related co-morbidities: upper urinary tract infection s 	guidelines state that a FAST stage 7A is or less prognosis, <u>if</u> the patient also exhib- sepsis weight loss >10% w/in six months	The FAST scale has 7 stages: 1 which is normal adult 2 which is normal older adult 3 which is early dementia 4 which is mild dementia 5 which is moderate dementia 6 which is mod-severe dementia 7 which is severe dementia				
Tsai S, Arnold R. Prognostication in De	mentia. Fast Facts and Concepts. February 2006						
FAST: Functional Assessment Staging							
Check highest <u>consecuti</u>							
1. No difficulty either subje	ectively or objectively.						

- □ 2. Complains of forgetting location of objects. Subjective work difficulties.
- □ 3. Decreased job functioning evident to co-workers. Difficulty in traveling to new locations. Decreased organizational capacity. *
- 4. Decreased ability to perform complex tasks, instrumental ADL's, e.g., handling personal finances , difficulty shopping etc.
- □ 5. Requires supervision with ADL's (e.g. choosing proper clothing to wear for the day, season)

6. a) Needs assistance with dressing (e.g., may put street clothes on over night clothes, or have difficulty buttoning clothing) occasionally or frequently
 b) Unable to bathe properly (e.g. difficulty adjusting the bath-water temperature) occasionally or more frequently in the past weeks. *

- c) Inability to handle mechanics of toileting (e.g. forgets to flush the toilet, does not wipe proper or properly dispose of toilet tissue) occasionally or more frequently over the past weeks. *
- d) Urinary incontinence (occasionally or more frequently over the past weeks).
- e) Fecal incontinence (occasionally or more frequently over the past weeks).
- 7. a) Ability to speak limited to approximately a half a dozen intelligible different words or fewer, in the course of an average day or in the course of an intensive interview.
 - b) Speech ability is limited to the use of a single intelligible word in an average day or in the course of an intensive interview (the person may repeat the word over and over).
 - c) Ambulatory ability is lost (cannot walk without personal assistance).
 - d) Cannot sit up without assistance (e.g., the individual will fall over if there are not lateral rests [arms] on the chair).
 - e) Loss of ability to smile.
 - f) Loss of ability to hold head up independently.

* Scored primarily on the basis of information obtained from knowledgeable informant and/or category. Reisberg, B. Functional assessment staging (FAST), Psychopharmacology Bulletin 1988; 24: 653-659

The Mortality Risk Index (MRI), a composite score based on 12 risk factor criteria has been suggested as an alternative to FAST. Mitchell (2004) developed and then validated the MRI by examining data from over 11,000 newly admitted nursing home patients. Among patients with a MRI score of \geq 12, 70% died within 6 months. Compared to FAST Stage 7C, the MRI had greater predictive value of six month prognosis.

Mitchell SL, Kiely DK, Hamel MB, et al. Estimating prognosis for nursing home residents with advanced dementia. JAMA. 2004; 291:2734-2740.

Мо	ortality Risk Index Score (Mitchell)	Risk estimate of	Risk estimate of death within 6 months		
Points	Risk factor	Score	Risk %		
1.9	Complete dependence with ADLs	0	8.9		
1.9	Male gender	1.2	10.8		
1.7	Cancer	3-5	23.2		
1.6	Congestive heart failure	6-8	40.4		
1.6	O2 therapy needed w/in 14 day	9-11	57.0		
1.5	Shortness of breath	=12	70.0		
1.5	<25% of food eaten at most meals				
1.5	Unstable medical condition				
1.5	Bowel incontinence				
1.5	Bedfast				
1.4	Age > 83 y				
1.4	Not awake most of the day				

SUMMARY	DECISION SUPPORT	PATIENT EI	DUCATION/S	ELF MANAGEMI	ENT			
)	$ STEP 2 \rightarrow Step 3$	listed below						
nitiate palliative care discussion. Discuss prognostic uncertainty but begin assessment of patient's goals. Utilize Advance Directive to elicit patient's choice of surrogate decision - maker and end of life wishes.								
	Discussir	ng Prognosi:	5					
nurse, Chaplain, M 1. Determine wh 2. Before preser 3. Provide inform 4. Give fair warn 5. Present bad n 6. Pause. Allow 7. Listen and acl 8. Present as mu 9. Provide progn 10. Assess thoug	ate setting Who : Provider (Or patient's surr ISW, Translator (w/out custody if security leve at the patient knows; make no assumptions. (ting bad news, consider reviewing patient's c nation in small chunks. Check patient's unders ing – "I am afraid I have some bad news" – th news in a simple, direct manner. Be prepared the news to sink in. Wait for the patient to resp (knowledge/validate patient's emotions: feeling uch information as the patient wishes. Don't o ostic information using a range: few days to v hts of self-harm- offer Mental Health referral pecific follow-up plan ("I will see you again tor	el allows) (Examples: What ourse up till now standing frequer nen pause for a n to repeat inform pond. g numb, angry, s verwhelm with of veeks; 2-4 mont	at have the other d v. ntly. moment. ation and give add sad, fearful letail in the first cor hs	loctors/nurses told you? itional information as p nversation unless reque	?) atient requests ested.			
Ambuel B, Weissman DE. Deliver	ing Bad News – Part 1, 2nd Edition. Fast Facts and Concepts. Jul	y 2005; 6. Available at:	http://www.eperc.mcw.edu/	/fastfact/ff_006.htm.				
	Establishing E	End-of-Life G	oals:					
Initial goal after the p • What to say: "Gi • How can • What acti • What fea • If you hav • What do	 Initial goal is to develop a broad understanding of the patient's hopes and goals, then specific treatment decisions are made after the patient and health care team have developed an understanding of the patient's broader goals. What to say: "Given what we now know about your medical condition" How can we help you live your remaining life as you want to live it? What activities or experiences are most important for you to feel your life has quality? What fears or worries do you have about your illness or medical care? If you have to choose between living longer and quality of life, how would you approach this balance? What do you hope for your family? 							
_	ave religious or spiritual beliefs that are impor e Goals: the Living Well Interview, 2nd Edition. Fast Facts and Co	Ļ	Available at: http://www.epe	erc.mcw.edu/fastfact/ff_065.htm.				
Advance Directive	for Health Care	POLST-P	hysician Order	s for Life-Sustainin	g Treatment			
Advance Directive for H Appropriate for all Patient completes Four parts: Part 1: Po Part 2: In Part 3: Do Part 4: Ve Witnesse Notary not require PA's, NP's, RN's, responsibility for th Filed in UHR- und Bright orange stick	Health Care CDCR Form 7421 patients regardless of age and health status form– discusses with PCP ower of Attorney for Health Care structions for Health Care onation of Organs at Death erification of Understanding, Signature,	Physician Ou Appropri- threater Provide Four pa * * * * * * * * * * * * *	rders for Life-Susta riate for patients wh ning illness or injury r completes form to rts: Part A: Resuscita Part B: Medical Ir Comfort Measure Interventions) Part C: Artificially yes/no/limited tria Part D: Signature UHR– in Physiciar range sticker place	aining Treatment (POLS no are frail, elderly or have preflect patient's wishe ation Status (CPR-yes/r nterventions (Intensity of so Only vs Full Treatme Administered Nutrition al). s/Summary of Medical ns Orders section	ST) Form 7388 ave a life s of Care– nt vs Limited (Feeding tube Condition			
		ep 3 👔	<u> </u>					
Assess patient's pall	iative care needs including the domains b		e care can be pro	ovided even as curati	ve treatment			
is attempted. The overriding goal of illness, including the po ICSI (Institute for Clinic	palliative care is to reduce suffering and main eriods of advanced illness and active dying. S cal Systems Improvement) recommends asse	ntain an accepta Specific goals of	able quality of life the palliative care inclu	hroughout the course c ude ensuring that:	of a progressiv			
 Physical Aspects Psychological Aspects 			ous Aspects of C	are				

Social Aspects of Care ٠

- ٠
 - Ethical and Legal Aspects of Care
- **Cultural Aspects of Care** ٠

Acetaminophen 325 mg tablets Rectal suppose. 650 mg Ibuprofen 200, 400, 600, 800 mg tablets Suspension 100mg/5 ml

STEP 4 Develop or revise the palliative care plan. Document the plan in progress notes & consider whether the patient meets criteria for Compassionate Release or Medical Parole. IAHPC* LIST OF ESSENTIAL MEDICINES FOR PALLIATIVE CARE FORMULATION COMMENTS IAHPC INDICATION MEDICATION PALLIATIVE CARE Pain-mild to moderate Can be useful in bone and soft tissue pain Pain-mild to moderate Long term use limited by GI bleeding risk and renal effects

Codeine Acetaminophen/ Codeine	15, 30, 60 mg tablets (NF) 30/300 mg tabs Elixir 12/120 /5ml	Weakest of the opioid analgesics and may result in greater constipation. May be good for cough.	Pain—mild to moderate Diarrhea
Methadone	5-10 mg tablets Soln: 10mg/mL DOT/NAT only, crush & float	 Initial dose : First 3-5 days in opioid naïve patients 2.5 mg-5mg q 8-12 h [Max 2.5 mg q 8-12 h in elderly] Titrate: Long and variable half-life makes titration difficult Methadone accumulates with repeated doses and dose reduction may be needed after 3-5 days to prevent CNS depression. Full effect 2-4 weeks Consult with pain specialist or pharmacist if not experienced with methadone use. ECG baseline, month 1, annually Prolongs QT interval– (see CCHCS Pain Management Guidelines for details). 	Pain—moderate to severe
Morphine	IR: 15-30 mg tablets SR: 30 mg tablets Soln: 10mg/5ml DOT/NAT only Cannot crush SR	 In acute or uncontrolled pain use immediate release (IR) Titrate using IR then switch to SR with breakthrough doses Frequent dosing of IR morphine required, may not be feasible in General population setting. Initial dose: Morphine IR 5 mg po q4h (See Breakthrough below) Titrate : ↑ dose by 30-50% of the previous dose – (depending on the severity of the pain) Alternatively new dose can be determined by adding the total of the breakthrough doses to the current dose. (e.g. Current dose 120 mg/day; breakthrough doses used in past 24 H = 60 mg : new dose 120 + 60 = 180 mg/day given as morphine IR 30 mg q4h) Breakthrough: Dose usually 10% of total daily opioid dose given prn (immediate release) between scheduled opioid doses 	Pain—moderate to severe Dyspnea
Fentanyl (transdermal patch)	25 micrograms/hr (NF) 50 micrograms/hr (NF)	For patients unable to swallow or GI compromised; difficult to ti- trate. Should be used only under guidance of Palliative Care/ or Hospice specialist or oncologist.	Pain—moderate to severe
Tramadol	50 mg tablets 100 mg/1 ml oral solution (NF) 50 mg/ml injectable	Can lower seizure threshold.	Pain—mild to moderate

CCHCS Care Guide: Palliative Care

FOR

PATIENT EDUCATION/SELF MANAGEMENT

DECISION SUPPORT SUMMARY

SUMMARY

DECISION SUPPORT

PATIENT EDUCATION/SELF MANAGEMENT

STEP 4 (cont.)

Develop or revise the palliative care plan. Document the plan in progress notes & consider whether the patient meets criteria for Compassionate Release or Medical Parole.

MEDICATION	FORMULATION	COMMENTS	IAHPC INDICATION FOR PALLIATIVE CARE
Carbamazepine	200 mg tablets	Adjuvant for chronic pain–Use with caution in patients undergoing marrow-suppressant therapies such as chemo or radiotherapy. Periodic monitoring of CBC is recommended Initial dose 100 mg b.i.d p.o. increase over 2 weeks to a maximum of 400 mg t.i.d	Neuropathic pain
Gabapentin	Tablets 100, 300, 400, 600 or 800 mg (NF)	Adjuvant for neuropathic pain–Generally start at 100-200 mg bid Titrate over 2 weeks to maximum 1800-3,600 mg/24 h divided bid	Neuropathic pain
Bisacodyl	5 mg tablets 10 mg rectal suppositories	Stimulant laxative-do not use in undiagnosed abdominal pain or if obstruction or ileus present.	(Bowel med)
Senna	8.6 mg tablets (187-600 mg) (NF)	Contact cathartic; for opioid induced constipation	Constipation
Loperamide	2 mg tablets	Loperamide should also be available if drugs that can cause diarrhea are prescribed. Discontinue when no longer needed.	Diarrhea
Metoclopramide	5, 10 mg tablets Injectable 10 mg/2 ml	Generally first line treatment for nausea Used for anorexia due to early satiety and gastroparesis.	Nausea/ Vomiting
Prochlorperazine (Compazine)	5—10 mg tablets Injectable 5 mg/ml	Good for opioid related nausea. Usual adult Dose: 5-10 mg po Q6-8h	Nausea/ Vomiting
Promethazine (Phenergan)	25 mg tablets Injectable 50 mg/ml Rectal Suppository 25 mg	Caution: Respiratory Depression. Adult Dose: 12.5-25 mg po / IM / IV Q4-6h	Nausea/ Vomiting
Dexamethasone	0.5, 0.75, 4, 6 mg tabs Injectable:4 mg/ml	Starting dose is empiric and varies widely: Dexamethasone 2-8 mg t.i.d to q.i.d p.o. or s.q. Can reduce cerebral and spinal cord edema. Is occasionally used in bone or neuropathic pain. Potential early side effects are loss of glucose control, increased risk of infection and acute psychiatric disorders.	Anorexia Nausea/Vomiting Neuropathic pain
Haloperidol	0.5, 1, 2, 5, 10 mg tabs Oral Soln: 2 mg/ml Injectable: 5mg/ml	Used in Terminal Delirium (0.5-1.0 mg q 8-12 hrs) and occasionally for nausea unresponsive to first line agents.	Delirium Nausea/Vomiting Terminal restlessness
Citalopram (Clexa)	10 , 20, 40 mg tablets	If depression suspected consult with Mental Health. Depresent the consult of any other equivalent generic SSRI except paroxetine and fluvoxamine.	
Lorazepam	1 mg tablets Injectable 2 mg/ml	If significant anxiety or insomnia consult Mental Health Used occasionally as adjuvant to treat dyspnea and nausea	Anxiety Insomnia
Megestrol Acetate	20, 40 mg tablets Oral Soln: 40 mg/ml	Can produce temporary appetite stimulation. No survival benefit has been shown. Caution: thromboembolism.	Anorexia
	·	Symptom Management	

tigue, excessive secretions, dyspnea, cough, anorexia/cachexia, constipation, nausea and vomiting in the palliative care or hospice patient based on recommendations from:

The International Association for Hospice and Palliative Care Manual of Palliative Care, 2nd Edition

Alberta Hospice Palliative Care Resource Manual 2nd Edition 2001

		D	IST	EP 4 (cont.)	
Develop or revise the palliative care pla whether the patient meets criteria for Co				ent the plan in progress notes & consider	
Causes / Evaluation		General Meas		Medications	
PAIN					
 Chronic Conditions: Early in course of progressive chronic illness it may be appropriate to follow Chronic Pain Guidelines. (See CCHCS Pain Management Guidelines). Once patient's disease progresses shift pain management strategy to "malignant pain". Palliative Care/Malignant Pain: More aggressive dosing Addiction and dependence not a concern Goal is to improve quality of life as the patient dies. Petermine nature and possible causes: Examples of causes of pain in palliative care patients neude pain: Due to the primary disease e.g.: tumor infiltration nerve compression Associated with treatment e.g.: diagnostic/staging procedures surgery Due to general debilitating disease e.g.: pressure sores Other comorbid conditions e.g.: arthritis 	tumor inf Occupati Supports fractures Relaxatio General Mea Use a Provid Use th Maxim varies + I f Opioion respon + (L C C C C C C C C C C C C C	 Consider radiotherapy for the control of bone pain and tumor infiltration. Occupational and physical therapy Supports such as collars and slings to immobilize fractures Relaxation therapy General Measures for Medication dosing: Use a regular schedule not solely PRN Provide breakthrough dosing Usually 10% of total daily opioid dose Can dose as frequently as q 1 H if setting permits Use immediate release (IR) formulation of patient's SR med if possible Anticipate and treat side effects Use the oral route wherever possible Maximum opioid dose limited only by toxicity and varies widely. If treating malignant pain and dose needed is ↑↑ contact hospice or palliative care specialist for guidance. Opioid rotation sometimes needed due to poor response or toxicity Calculate total daily opioid dose including breakthrough doses.		 Mild -Moderate pain Start with a non-opioid acetaminophen 325 -650 mg q4hr po or Ibuprofen 400-800 mg bid-t.i.d or codeine 30-60 mg q4hr po regularly Moderate-Severe pain After optimizing dose of above switch to a stronger opioid (<i>e.g.</i>, morphine or methadone) See page 7 for dosing Opioids are treatment of choice Adjuvants may be used but <i>first</i> optimize the opioids Adjuvant analgesics are less reliable than the opioids for cancer-related pain and have troublesome side effects. Avoid polypharmacy where possible in order to minimize adverse effects. 	
STOMATITIS Can range from mild inflammation to ulceration that an bleed or become infected. Causes of stomatitis • Infection • Medication (e.g. chemotherapy) • Radiotherapy • Poor dental hygiene • Poorly fitting dentures • Blood dyscrasias	(if the patient tinely withEnsure constructionUse wate petroleur	regular mouth care bef atient is able to eat) and th other care, (e.g. q2h t dentures are properly fitt er soluble lip balms or lu m based products, to ke outhwashes that contair mucosa.	d at bedtime; or rou- urns). ed. ıbricants, rather than ep lips moist.	 If pain is severe, suggest analgesic rinses with xylocaine 2%. Treat candidiasis or thrush with nystatin, fluconazole or ketoconazole. Oral medications should be swallowed as thrush may extend into the esophagus. Patients on immunosuppressive drugs should be examined regularly for thrush. Treat herpes simplex; consider acyclovir. 	
	E	Equianalgesic [Dosing		
Medication		PO Dose		SC/IV Dose	

Medication	PO Dose	SC/IV Dose
Codeine	100 mg	50 mg
Morphine	10 mg	5 mg
Methadone †	1 mg	too irritating
Oxycodone * (NF- May be stated at outside hospital)	5 mg	
Hydromorphone (Dilaudid NF)	2 mg	1 mg
Fentanyl patch (Use limited to hospice or oncologist)	use chart supplied by manufacturer	

The equianalgesic dose ratio of morphine to oxycodone is controversial. It appears to be between 1.5:1 and 2:1.

T Many tables quote the equianalgesic dose ratio of morphine to methadone as being 1:1, i.e., morphine 1 mg po = methadone 1 mg po. This ratio was dottermined in cancer pain, when multiple doses are required, the ratio of morphine to methadone becomes approximately 10:1, i.e., morphine 10 mg po = methadone 1 mg po. Many tables quote the equianalgesic dose ratio of morphine to methadone as being 1:1, i.e., morphine 1 mg po = methadone 1 mg po. This ratio was determined using single dose studies.

From: Alberta Hospice Palliative Care Resource Manual 2nd Edition 2001

DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT SUMMARY STEP 4 (cont.) Develop or revise the palliative care plan. Document the plan in progress notes & consider whether the patient meets criteria for Compassionate Release or Medical Parole. **Causes / Evaluation General Measures** Medications **ANXIETY / DEPRESSION** Social supports provided by current prison Anxiety and depression are common in For anxiety community, outside family and friends and seriously ill patients and ↓quality of life. Short acting benzodiazepines, e.g., religious groups are important. • Can cause physical symptoms such as Lorazepam 0.5-1 mg g 6 hrs prn. nausea, dyspnea and insomnia. Patient education is vital. Correct miscon-Emphasis on supportive measures rather ceptions regarding the illness, treatment or than pharmacological modalities. **Evaluate** the dying process. Chronic anxiety often responds to SSRI's It is important to differentiate grief from depression. Legitimize the difficulty of the situation -In depression Grieving can be an appropriate response the "right" to be upset reduces the fear of · Selective serotonin re-uptake inhibitors to loss, but persistence of symptoms manbeing perceived to be "weak" or (SSRI's) are drugs of first choice. dates consideration of depression. "inappropriate." Mental Health provider will need to Always assess for suicidal risk. • evaluate the patient and prescribe Respect the desire of the patients to • Look for clinical conditions that may medication as needed. maintain hope. mimic depression and treat these: Antidepressant drug treatment is usually well Metabolic (e.g., hypercalcemia) Refer to mental Health if medications tolerated, some expert consensus state- Endocrine (e.g., hypothyroidism) are needed. ments recommend a low threshold for treat- Drugs (eg., anticonvulsants, ment, but evidence on the effectiveness of beta-blockers, corticosteroids, antidepressants at the end of life is poor. tamoxifen) DELIRIUM · Delirium is a clinical syndrome, not a dis-Drug of choice for most patients is a Non-pharmacological treatments should ease in itself. neuroleptic, usually haloperidol. This class of always be used first in delirium • Prevalent in patients with preexisting demanagement. drugs calms patients without interfering with mentia. cognition. Keep an eye out for things such as urinary Common in the week or two before death. Haloperidol start at 0.5-1 mg po/sg g 8-12 retention, constipation, uncontrolled pain, Common causes of delirium include: hrs and 1 mg q1h po/sq prn for agitation. kinked oxygen tubing, etc. Titrate up as needed . Drugs (anticholinergics, antihistamines, Reduce the sensory stimulation in the anti-emetics, sedative hypnotics, and environment as needed. opioids)- discontinue drug if possible Metabolic abnormalities (\uparrow Na+, \uparrow Ca+2, hypoglycemia, hypoxia, etc). Dehydration • Infections ٠ CNS pathology-brain metastases • FATIGUE Non-pharmacologic treatment includes: Medications that may make the patient Fatigue may be a consequence of the • more tired should be administered at primary illness or of the treatments used patient education about fatigue • bedtime rather than in the morning. (such as radiation and chemotherapy). modifying the activities of daily living • scheduling rest periods during the day • *Erythropoietin* should be reserved for very Evaluate for underlying causes (such as • select patients with documented aneanemia or hypoxia). · Clinicians should counsel patients to mia under the care of an oncologist due to prioritize activities and pace themselves Management includes treating the • the high cost of treatment and lack of eviaccordingly. underlying cause as well as using dence of benefit in other clinical situations non-pharmacologic and pharmacologic Mild exercise for brief periods may be therapy directed toward the symptom itself. beneficial in reducing the perception of fatigue for some patients **EXCESSIVE SECRETIONS** Position the patient on their side or semi-The drug class of choice is muscarinic As the level of consciousness decreases in receptor blockers (anti-cholinergic drugs). prone to facilitate postural drainage. the dying process, patients lose their ability to These include: Gentle oropharyngeal suctioning is used swallow and clear oral secretions. • Scopolamine-Transderm Patch 1.5 mg q3d although ineffective when fluids are beyond Hyoscyamine (Levsin) 0.125 mg po/SL the reach of the catheter. ٠ Atropine 0.1 mg SQ/IV Reduction of fluid intake.

limited to terminally ill patients who are taking for

another indication.

DYSPNEA

PATIENT EDUCATION/SELF MANAGEMENT

STEP 4 (cont.) Develop or revise the palliative care plan. Document the plan in progress notes & consider whether the patient meets criteria for Compassionate Release or Medical Parole. **General Measures** Medications **Causes / Evaluation** Dyspnea is a subjective symptom, and may General measures such as: Opioids are drug of choice: or may not be accompanied by hypoxia. · calm, reassuring attitude Dosing Causes Morphine IR 5mg-10 PO Q3-4H, titrated for effect. • positioning (sitting up) • Airway obstruction: tumor. infection. bronchospasm. (May be converted to Morphine SR once effective • increasing air movement via a fan or open • Impaired ventilatory movement: chest wall dose established.) window weakness, ascites. SQ is guicker acting, but must be dosed more · use of bedside relaxation techniques are all help-Cardiovascular: CHF, anemia, pericardial effusion. frequently. • ful No ceiling dose when titrated for effect. Evaluate In the imminently dying patient, discontinu-• Other opioids may help, but Morphine is "gold Consider simple problems: ing parenteral fluids is appropriate. standard". - Is the Oxygen turned on? Treatment with oxygen is often, but not - Is the tubing kinked? Anxiolytics can reduce the anxiety component of universally, helpful. When in doubt, a thera-If the patient is clearly dying and the goal is comfort, dyspnea. peutic trial, based on symptom relief, not then pulse oximetry, arterial blood gases, EKG, or Lorazepam 0.5-2mg Q4-6H PO/SQ/SL prn pulse oximetry, is indicated. imaging are not indicated. Observe for sedation Nebulized bronchodilators and/or steroids can be used if bronchospasm noted. COUGH Causes Nonpharmacologic therapy is directed at the Opioids suppress cough, but there is no sci-Airway irritation: tumor, GERD, infection, post-nasal • symptom rather than the underlying etiology. entific evidence allowing comparison of one drip, aspiration. opioid with another. Goal is to control rather than eliminate cough. Lung pathology: infection, tumor, fibrosis, pulmonary • • Codeine 8-20 mg PO q 4-6 h edema, COPD. · Humidify air, Saline via nebulizer. • Morphine 2.5-5 mg PO q 4-6 h Irritation of other structure associated with cough • • Avoid fumes. For patients already using substantial doses of • reflex: pleura, pericardium, diaphragm. Proper positioning reduces coughing sec-• opioids, one might increase the dose by 20% every ondary to reflux or aspiration. **Evaluate** 24-hour period, until control of coughing or side Chest physiotherapy helps expectorate • H&P and CXR usually define the cause. effects. mucus. • Whether investigations should be done depends on Dextromethorphan 10-20 mg PO g 4-6 h may have patients goals of care and patients stage in the a synergistic effect with opioid terminal illness trajectory. Little evidence to support the use of nebulizer in the management cough related to malignancy, or chronic cardiac disorders. May be effective if underlying COPD or asthma. **ANOREXIA/CACHEXIA** Anorexia refers to the loss of desire to eat. • Control nausea with gastric motility agent: Frequently offer easily eaten small portions. • Cachexia refers to weight loss, especially Minimizing dietary and consistency restric-Metoclopramide 10 mg po gid of lean body mass. tions may tempt the patient to improve his Risk of pressure sores. Stimulation of appetite:. or her intake. Primary Anorexia/Cachexia Syndrome is due to a Megestrol Acetate starting at 160 mg/day and The role of medical nutrition and hydration (also known complex of abnormal metabolic, neuroendocrine and increasing up to 800 mg/day depending on response. as artificial nutrition and hydration) is not clear cut. immunological pathways e.g. induced by the tumor. • Associated with an ↑ risk of thromboem-• The patient's end of life preferences should be Secondary Cachexia Potentially reversible causes of bolic events, peripheral edema, hyperglyrespected. Anorexia/ Cachexia including: cemia, ↑ BP, and adrenal suppression. A recent meta analysis of randomized clinical trials For most conditions, there is scant studying the effectiveness of nutritional supplementa-• Factors causing 1 food intake or impaired GI absorpinformation about improved quality of life, tion (either oral, or via enteral or parenteral routes) tion, e.g. dysphagia, nausea, depression, diarrhea. identified no evidence for clinical benefit in a variety and no survival benefit has been shown. • Catabolic states e.g. infection, poorly controlled of clinical settings, including cancer, chronic lung or diabetes. Dexamethasone 4-10 mg bid has been used but liver disease, and critical care settings (Koretz, 2007). because of significant side effects it should generally be

Loss of muscle mass due to decreased muscle • activity e.g. prolonged inactivity.

SUMMARY

DECISION SUPPORT

SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT

ISTEP 4 (cont.)

Develop or revise the palliative care plan. Document the plan in progress notes & consider whether the patient meets criteria for Compassionate Release or Medical Parole.

Causes / Evaluation	General Measures	Medications
CONSTIPATION & BOWEL CARE		
 Common causes Poor oral intake or dehydration. Malnutrition: related to the anorexia/ cachexia syndrome. Poor fluid intake. Drugs: opioids, anticholinergic drugs, diuretics, iron, etc. Decreased mobility. Abdominal tumors. Hypokalemia, hypercalcemia. N.B.: Patients can become constipated even if they are not eating! Diagnosing constipation Can present as diarrhea Perform a digital rectal examination. Occasionally a plain abdominal radiograph may assist in the diagnosis. 	 Prevention General measures: encourage generous fluid intake (8-10 glasses/day). FIBER NOT HELPFUL as patient becomes debilitated. Encourage exercise as tolerated. Suggested bowel routine for patients on regular opioids: When starting a patient on an opioid, start laxatives simultaneously and give regularly not prn. Start with a bowel stimulant and a stool softener (eg: senna 1-2 tabs h.s. + docusate 100 mg-200 mg bid po.) Adjust dosages and frequencies as needed to ensure the patient has a soft, formed bowel movement every 1-2 days. Patients often require senna 2-4 tabs bid up to qid prn, and docusate 200 mg tid up to qid prn. If no bowel movement within 3 days, administer a fleet enema or Bisacodyl suppository rectally on day three. N.B.: One good response to a laxative or enema may not treat the constipation fully. The sigmoid may be clear but the rest of the colon may still be full of stool. 	 Treatment of established constipation If stool in rectum: Hard: glycerin suppository, Fleets enema, disimpaction. Soft: bisacodyl (Dulcolax) or docusate (Colace) suppository, Fleets enema disim- paction. If no stool in rectum: Do plain x-ray. No bowel obstruction: bisacodyl or docu- sate suppository, oral medication. Bowel obstruction: appropriate therapy. Doses Stool Softener: Colace 100mg 1-2 PO BID (also comes in liquid form for PEG tube feedings) Stimulant Laxative: Bisacodyl tablet 5 mg 1-2 po QD-BID Bisacodyl suppository 10 mg PR QD-BID Senokot (NF) Senna 2-4 tabs PO QD-BID Senokot (NF) Senna 2-4 tabs PO BID- QID. Milk of Magnesia (magnesium hydroxide 400mg/5 ml) 30ml PO TID-QID prn. Fleets enema (Sodium phosphates) Magnesium citrate (300 ml) 1 bottle in 24 hrs (especially if KUB shows large amount of stool in ascending or transverse colon).
NAUSEA/VOMITING		
 There are multiple reasons for nausea. Identifying the cause will help determine the best course of treatment. Cause - frequently due to multiple causes Irritation or obstruction of the GI tract:cancer gastritis, constipation, hepatitis, bowel obstruction, chemotherapy, gastric compression. Related to chemoreceptor trigger zone (CTZ): biochemical abnormality, ↑Ca+2, renal or hepatic failure, medication (opioids, antibiotics), sepsis. Related to cortical centers: sites, smells, tastes, anxiety, conditioned vomiting, raised intracranial pressure. 	 Avoid strong smells/perfumes Small meals, eaten slowly Limiting oral intake during periods of frequent emesis . Relaxation techniques. Cornerstone is pharmacologic therapy: Use in combination if necessary Give before vomiting starts is possible Match antiemetic medication to presumed causative mechanism. Prochlorperazine (Compazine) works on CTZ-preferred for opioid related nausea. Promethazine (Phenergan) muscarinic blocking effect may be responsible for antiemetic activity. Most useful in vertigo and gastroenteritis due to infections and inflammation. Metoclopramide (Reglan) direct gastroki- netic effect and works on CTZ. Ondansetron (Zofran) prevents vagal stimu- lation in Gl tract and may also have central action. Haloperidol (Haldol) works on CTZ. Chlorpromazine (Thorazine)works on CTZ. Lorazepam (Ativan) at cortical level. 	 Nausea Reglan 10mg PO/SQ Q6H prn or QID (AC and HS) (Good first-line as works on CTZ and GI. Contraindicated in bowel obstruction). Compazine 10mg PO/SQ/PR Q6H prn Phenergan 25mg PO/IM Q6-8H prn Nausea (persistent) Ondansetron 4-8mg PO BID-QID (NF). Decadron 4mg PO/SQ/IV Q6H may help in nausea associated with chemotherapy, radiation, increased intracranial pressure Lorazepam 0.5-2mg PO/SQ/IV/IM Q6H prn may help in anxious patient as adjuvant. Haloperidol and Thorazine may be effective, but should only be used if other modalities are ineffective.

July 2011

DECISION SUPPORT

PATIENT EDUCATION/SELF MANAGEMENT

STEP 5

CCHCS Care Guide: Palliative Care

Consider Hospice Criteria. Hospice entry criteria are based on medical findings. However decisions to admit patients to hospice are influenced by nonmedical factors such as the patients decision to forgo life-prolonging care and focus on symptom management. Emphasis should be placed on evaluating the whole person and the entire burden of their illnesses). A patient may have multiple medical problems, none of which taken individually amount to terminal condition, but when taken together do indicate a terminal condition.

	Palliative Care	Hospice
Debility/ Failure to Thrive	 Greater than three chronic conditions in patient over 75 years old Functional decline Weight loss Increasing frequency of outpatient visits, emergency department visits, hospitalizations 	 Documentation of clinical progression of disease ECOG score of three or more No desire for aggressive treatment Not a candidate for aggressive treatment Frequent emergency room visits/frequent hospitalizations
Cancer	 Uncontrolled signs and symptoms due to cancer or treatment Introduced at time of diagnosis - if disease terminal Introduced when disease progresses despite therapy 	 Aggressive or progressive malignancy with increasing sx , worsening lab values or evidence of metastases Palliative Performance Score < 70% Patient does not want further curative intent therapy Decline supported by: Ca+2 > 12, WT Loss <a>5% in past 3 mos, recurrent disease after radiation or chemotherapy, S/S of advanced disease (i.e. malignant ascites, pleural effusion, need for transfusions) Generally need tissue diagnoses (explain if not available)
Heart Disease	 Stage III or IV heart failure despite optimal medical management Angina refractory to medical or interventional management Frequent emergency department visits or hospital admissions Frequent discharges from implanted defibrillators despite optimal device and antiarrhythmic management 	 Heart failure symptoms at rest (NYHA Class IV) Recurrent episodes HF despite optimal medical RX Ejections fraction less than 20% Rx resistant supraventricular or ventricular arrhythmias H/O Cardiac arrest or resuscitation H/O unexplained syncope Brain embolism of cardiac origin (recent) Concomitant HIV disease
Pulmonary Disease	 Oxygen-dependent, O2 saturation less than 88% on room air Unintentional weight loss Dyspnea with minimal to moderate exertion Other pulmonary diagnoses, e.g., pulmonary fibrosis, pulmonary hypertension 	 End Stage pulmonary disease documented by :Dyspnea at rest, ↓ functional capacity (bed to chair), fatigue, ↑ED visits or hospitalizations for infections and/or respiratory failure Hypoxia at rest with O2 saturation ≤ 88% or pO2 < 55 mmHg on supplemental oxygen or hypercapnia PCO2 > 50 Supportive evidence: right heart failure due to pulmonary disease, WT Loss >5 % over past 3 mos, resting pulse >100
Dementia	 Behavioral problems Feeding problems - weight loss Frequency of ED visits Increased safety concerns 	 Unable to walk, bathe or dress self without assistance Incontinence Less than six intelligible words Frequent ER visits
Liver Disease	 Increased need for paracentesis for removal of ascitic fluid Increased confusion (hepatic encephalopathy) Increased safety concerns Symptomatic disease 	 INR > 1.5 with albumin <2.5 gm/dl Evidence ESLD with refractory ascites or encephalopathy, SBP, recurrent variceal bleeding, or Hepatorenal syndrome One of the following: WT Loss >5% in 3 mos, muscle wasting or Hepatocellular carcinoma
Renal Disease	 Dialysis Stage IV or Stage V chronic kidney disease 	 Not a candidate for dialysis or refuses dialysis Creatinine clearance < 10 mL/min (< 15 mL/minute if DM) Serum creatinine > 8.0 (> 6.0 if DM) Supportive Comorbid conditions: advanced heart, lung, or liver disease, malignancy, AIDS, age >75, alb <3.5 Supportive S/S uremia, intractable ↑K+, fluid overload
Neurologic	Stroke Parkinson's ALS - amyotrophic lateral sclerosis MS - multiple sclerosis	 Frequent emergency room visits Albumin less than 2.5 Unintentional weight loss Decubitus ulcers Homebound/bed confined

Based on Institute for Clinical Systems Improvement (ICSI) Health Care Guideline: Palliative Care Third Edition 2009

Hospice criteria based on National Hospice and Palliative Care Organization (NHPCO) criteria and are consistent with CMF criteria.

SUMMARY

SUMMARY DECISION SUPPORT PA

PATIENT EDUCATION/SELF MANAGEMENT

STEP 5 (cont.)

Consider Hospice Criteria. Hospice entry criteria are based on medical findings. However decisions to admit patients to hospice are influenced by nonmedical factors such as the patients decision to forgo life-prolonging care and focus on symptom management. Emphasis should be placed on evaluating the whole person and the entire burden of their illnesses). A patient may have multiple medical problems, none of which taken individually amount to terminal condition, but when taken together do indicate a terminal condition.

Women-CCWF

Central California Women's Facility (CCWF) has a Skilled Nursing Facility (SNF) where Palliative or Comfort Care (CC) is provided. Comfort Care admission criteria:

- The SNF attending Physician, CMO or designee certifies a prognosis of six months or less if the disease follows its expected course.
- The patient-inmate and or designated legal representative agree to Palliative/CC goals/philosophy of CC services.
- The SNF has the ability to meet the needs of the patient-inmate, according to the level and intensity of care required.
- There are adequate, cooperative efforts by the patient-inmate to follow safety measures and the plan for medical and non-medical emergencies.
- A Do not Resuscitate (DNR) must be signed and on file for the inmate-patient

Providers with women inmates meeting the criteria and requesting comfort care can contact the Medical Executive at CCWF.

Men-CMF

California Medical Facility (CMF) has a 17 bed Hospice unit that accepts referrals from all CDCR (men's) institutions. The CMF Hospice uses an interdisciplinary team approach in care planning and delivery. This closed unit attempts to maintain the patient in an inpatient setting as homelike as possible within the prison. Family visits are facilitated.

- Admission Criteria: General criteria see below, disease specific criteria see page 13.
 - Prognosis 6 mos or less- if prognostic uncertainty contact Hospice staff to discuss patient
- Custody requirements: Custody C&PR reviews each Hospice referral to see if custody level allows for admission. (Some custody levels require housing in a single cell only and single rooms are limited.)
- Waiting List: Varies but often there is no waiting list and providers are encouraged to communicate with CMF if they have an urgent referral.

Providers with men meeting the criteria and requesting Hospice care should contact Frank Santos, CMF Hospice Administrator at (707) 453-4009 to request a referral package.

CMF Hospice Referral Requirements- What Referring Institution Must Submit:

Al	l Patients:		
1.	Current Medication Profile (both CDCR and outside hospital)	7.	Progress note stating that the patient has 6 months or less to
2.	Last 3 months and other pertinent labs		live
3.	All relevant imaging (x-ray, CT, other)	8.	Advance Directive / DNR (if one exists)
4.	Last 3 months of physician progress notes	9.	Pre-Transfer Checklist
5.	H&P done within the last 30 days	10.	Level of Care Assessment
6.	Hospice Agreement	11.	Discharge Summary

CMF-General Criteria for all Patients Considered for Hospice

Patient has either of the following:

A. Documented clinical progression of disease:

- 1. Progression of primary disease as listed in the disease-specific criteria, documented by serial physician assessment, laboratory, radiologic or other studies.
- 2. Multiple Emergency Department visits or inpatient hospitalizations over the last six months
- 3. For patients who do not qualify under 1 or 2, a recent decline in functional status may be documented:
 - A. Recent functional decline to distinguish patients who are terminal from those with reduced baseline.
 - B. Functional status may be documented by:
 - Karnofsky Performance Status
 - ECOG
 - PPS
 - Dependence in 3 of 6 activities of daily living ADL's are: Bathing, dressing, feeding self, transfer (chair to bed, lying to sitting), continence of urine and stool, and ability to ambulate outside of cell.

B. Documented recent impaired nutritional status related to the terminal process.

- 1. Unintentional, progressive weight loss of >5% over the last 3 months.
- 2. Serum albumin less than 2.5gm/dl is helpful, but not used in isolation from other factors.

SUMMARY

DECISION SUPPORT

PATIENT EDUCATION/SELF MANAGEMENT

WHAT YOU SHOULD KNOW

Q: What is Palliative Care?

- Palliative care has also been known as "Comfort Care".
- Palliative care is medical care that tries to keep patients with serious medical illnesses comfortable.
- Palliative care tries to help patients with their worries, fears and stress as well as any pain or other physical problem they may have.
- Palliative care can be started at any time in the patient's illness, even when there is still hope for a cure.
- Palliative care can be provided by most, if not all, doctors, physician assistants, NP's and nurses.
- Palliative care can be done in many places (including General Population, OHU, CTC or hospital) depending on a persons illness and what medical needs they have at that time.

Q: What is Hospice?

- Hospice care also tries to keep patients comfortable as they die.
- Hospice care is usually used when a person has six months or less to live.
- Hospice care is given by a team made up of doctors, nurses, social workers, and Chaplains who work together to keep the patient comfortable.
- Hospice care tries to help the patient deal with any "unfinished business". If the patient wants getting in touch with family or wants religious support the hospice team can usually help.
- In CDCR hospice care is offered at CMF for men, and hospice-like comfort care is offered at CCWF for women.
- Most of the time your Primary Care doctor or cancer doctor will ask you if you are interested in the hospice program when the time is right.
- You are welcome to ask your doctor about hospice care at any time if you have questions.

Q: Do you have to have cancer to be accepted into hospice?

• No, persons with many types of illnesses (such as Heart Failure, liver disease, COPD, dementia, kidney failure) are allowed into hospice.

Q: Do you have to be in hospice to be considered for Compassionate Release or Medical Parole?

• No, these programs are different and it does not matter if you are in hospice.

Q: What is advance care planning?

- Thinking ahead about what kind of medical care you want as you get sicker.
- The kind of medical treatment you want usually depends on what is important to you.
- Talking about your wishes with loved ones and your doctors and nurses will help make sure that your wishes are followed.
- Writing down your wishes in an "Advance Directive" form is another way to be sure they will be followed. It's important to remember that...
 - Your wishes can be changed any time.
 - Advance care planning is done over time and your wishes may change as your health changes.
 - It is best to think about what you want before you get really sick

Q: What is an Advance Directive?

- Advance directives are papers that allow you to write your wishes about end of life care.
- They allow you to say what you want so that family, friends, doctors and nurses will know for sure what you want if you can no longer speak for yourself.
- In CDCR we use CDCR Form 7421 Advance Directive for Health Care .
- You may request an CDCR Form 7421 at anytime, even when you are young and perfectly healthy.
- The Form 7421Advance Directive allows you to:
 - Name someone to speak for you when you can no longer speak for yourself (called a surrogate/agent)
 - Say what your wishes are (e.g. "I don't want CPR, or a breathing machine", "feeding tube ok")

SUMMARY

DECISION SUPPORT

PATIENT EDUCATION/SELF MANAGEMENT

WHAT YOU SHOULD KNOW

Q: What is a Health Care Surrogate/Agent?

- A health care surrogate (also called an agent) is a person that you pick to make health care choices for you when you cannot speak for yourself.
- The health care surrogate is very important.

What a Health Care Surrogate Can Do (once you can longer speak for yourself)

- Talk with your doctor about your medical problems and agree to start or stop medical treatments including: medicines, tests, CPR, breathing machines (ventilators), feeding tubes
- Tell others about your end of life wishes and make sure they are followed

Choosing a Health Care Surrogate:

A health care surrogate is often a family member, but does not need to be. He/she should be someone who:

- you can trust;
- will be able to talk with your family
- is willing to do the job
- knows about what you want

Your Health Care Surrogate cannot be your doctor or other medical provider.

Q: What is a DNR order?

- A do not resuscitate (DNR) order is another way you ask that your wishes are followed.
- DNR is a request not to have cardiopulmonary resuscitation (CPR) if your heart stops or if you stop breathing.
- In most cases doctors and nurses will try to help all patients if their heart stops or if they stop breathing by doing CPR unless the patient has asked not to have this done.
- Unfortunately when a person has a serious or terminal illness CPR does not usually work and trying it can cause the person more pain and only slow their dying.
- In CDCR a POLST form (see below) is used to allow a patient to say whether he or she wants or does not want CPR to be tried.

Q: What is a POLST?

- POLST is short for Physicians Orders for Life Sustaining Treatment.
- This is a form that is used by all hospitals in California (and other states).
- In CDCR POLST Form 7385 is used to write a patient's wishes about end of life care.
- The POLST allows a patient to say:
 - Try CPR or Do Not Try CPR (Allow Natural Death)
 - I want comfort care only or I want full treatment (or something in between).
 - I want a feeding tube tried or I don't want a feeding tube tried.
- If you are seriously ill, especially if you have been in the hospital your doctor should talk with you about filling out a POLST.
- If your doctor has not asked about your wishes, you should bring it up yourself so that any questions you have can be answered and your wishes can be written down and followed.



SUMMARY

PATIENT EDUCATION/SELF MANAGEMENT

WHAT YOU SHOULD KNOW Myths About Death and Dying: • In the United States death is often hidden away in the back rooms of hospitals. Many people do not like talking about death even though death is a normal part of life. "Death is too frightening to • In the past grandparents died at home and children learned death was a normal talk about" "It's not normal to part of life. talk bout death" Thinking about dying can be scary, but often learning more of the facts can make it less scarv. • Feel free to ask questions of your doctor or nurse. • This is one of the most common myths about dying. Many people die without having pain. "Dying is always painful" • If pain does occur, it can usually be treated and the patient can be made comfortable. • This is not true. • In the early 1980's the courts said that there is no legal difference between stopping a treatment once it is started and never starting the treatment. "It is not legal to stop a treatment such as a breathing ma- Patients or families can decide to withhold treatment that is not wanted (never chine once it is started". start it) Patients or families can decide to withdraw treatment that is no longer wanted (stop it) • There comes a time in some cases where giving the dying person food (tube feeding) and liquids is no longer helpful and so these are stopped. • For persons at the end of their life stopping or not starting tube feeding and fluids is not painful. • In fact the opposite is true: giving tube feeding and liquids to dying persons can prolong their discomfort and prevent nature from taking its course. • This is never done without a lot of thought. "No matter what the patient • The choice to withhold or stop tube feeding and/or liquids is must continue to be fed and be made only when it is clear that using them would not help. given liquids during the dying It is best to think about whether you would want tube feeding and discuss your process" wishes with your doctor and nurse.

July	120)11
Jun	/ 20	' ' ' '

SUMMARY	DECISION SUPPORT	PATIENT EDUCATION/SELF MANAGEMENT		
WHAT YOU SHOULD DO				
	MY END OF LIFE WISHES / VALUES			
physical com	fortrelief of pain and c	tant to you and you think about dying: distressto die naturally other		
able to care to care to care to care to care the care to care the care to care the care to care the care to	ving are important to your o for my physical needs about my care needs	recognizing family & friendsmaking my own decisionsreceiving palliative (comfort) care & hospice		
Have you thought a	about whether you would w	want to have CPR done?usedon't usenot sure		
Have you thought a	about whether you would w	want a feeding tube?usedon't usenot sure		
 Would you want to be kept alive by machines (ventilator) in the following cases?: If my brain's thinking functions were destroyed? 				
	leath with a terminal illness?			
	Are you a member of a religion?NoYes If yes, is there a person you would want to help attend to your spiritual needs as death nears? (Specific faith or congregation)			
If your medical team believes that your death is near is there a family member you would like to be told? (Must be on CDCR Form 127)				
Following your de	ath is there a family mem	ber you would like to be told? (Must be on CDCR Form 127)		
Are there other this communicate or y	• •	e to know about you, in the event that you become unable to		
	How do you feel about death and dying? (Have you had someone close to you die? Did that person's illness or medical treatment change your thinking about death and dying?)			
Note: Complete and	d share this with your doctor,	, family and caregivers.		
Μγ [DIAGNOSIS/MEDICATIONS	Advance Directives		
	you understand your medicaticatic you understand your medicatic team any questions you			
My major health co	onditions:	If so approximately when?		
		Who did you chose to speak for you if you can not		
		speak for yourself?		
 It is important to and why you are 	know what medications yo taking them.	u are taking		
Questions about m		POLST (CDCR Form 7385)		
		If so, approximately when?		